Hypoxia drives transient site-specific copy gain and drug-resistant gene expression

Genes and Development

Volumn 29, Issue 10, 2015, Pages 1018-1031

  Black, Joshua C ^a   Atabakhsh, Elnaz ^a   Kim, Jaegil ^b   Biette, Kelly M ^a   Van Rechem, Capucine ^a   Ladd, Brendon ^a   Burrowes, Paul D ^a   Donado, Carlos ^a   Mattoo, Hamid ^a   Kleinstiver, Benjamin P ^a,c   Song, Bing ^a   Andriani, Grasiella ^d   Keith Joung, J ^a,c   Iliopoulos, Othon ^a,c   Montagna, Cristina ^d   Pillai, Shiv ^a   Getz, Gad ^a,b   Whetstine, Johnathan R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

CNV; Hypoxia; JmjC; KDM4A; Site specific copy gain; Tumor heterogeneity

Indexed keywords

2,3 DIMETHOXY 1,4 NAPHTHOQUINONE; ACETYLCYSTEINE; CDC28 PROTEIN KINASE REGULATORY SUBUNIT 1B; CYCLIN DEPENDENT KINASE; HISTONE DEMETHYLASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; OXYGEN; REACTIVE OXYGEN METABOLITE; SUCCINIC ACID; UBIQUITIN LIGASE LYSINE DEMETHYLASE 4A; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; CKS1B PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL CYCLE S PHASE; CELL PROLIFERATION; CENTROMERE; CHROMOSOME 8; CONTROLLED STUDY; COPY NUMBER VARIATION; DEMETHYLATION; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC GAIN; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; HYPOXIA; HYPOXIC CELL; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE TEST; MULTIPLE MYELOMA; NEUROBLASTOMA; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; SPECTRAL KARYOTYPING; TRANSIENT SITE SPECIFIC COPY GAIN; UBIQUITINATION; WESTERN BLOTTING; ZEBRA FISH; ANIMAL; CELL CULTURE; CELL HYPOXIA; CELL LINE; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; PHYSIOLOGY;

DANIO RERIO;

ANIMALS; CDC2-CDC28 KINASES; CELL HYPOXIA; CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; DNA COPY NUMBER VARIATIONS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION; HUMANS; ZEBRAFISH;

EID: 84929578889     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.259796.115     Document Type: Article

References (49)

1. Alt FW, Kellems RE, Bertino JR, Schimke RT. 1978. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem 253: 1357–1370.
2. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, et al. 2010. The landscape of somatic copy-number alteration across human cancers. Nature 463: 899–905.
3. Beyer S, Kristensen MM, Jensen KS, Johansen JV, Staller P. 2008. The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. J Biol Chem 283: 36542–36552.
4. Black JC, Allen A, Van Rechem C, Forbes E, Longworth M, Tschop K, Rinehart C, Quiton J, Walsh R, Smallwood A, et al. 2010. Conserved antagonism between JMJD2A/ KDM4A and HP1γ during cell cycle progression. Mol Cell 40: 736–748.
5. Black JC, Van Rechem C, Whetstine JR. 2012. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell 48: 491–507.
6. Black JC, Manning AL, Van Rechem C, Kim J, Ladd B, Cho J, Pineda CM, Murphy N, Daniels DL, Montagna C, et al. 2013. KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors. Cell 154: 541–555.
7. Burrell RA, McGranahan N, Bartek J, Swanton C. 2013. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501: 338–345.
8. The Cancer Genome Atlas Network. 2012. Comprehensive molecular portraits of human breast tumours. Nature 490: 61–70.
9. Carreau A, El Hafny-Rahbi B, Matejuk A, Grillon C, Kieda C. 2011. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. J Cell Mol Med 15: 1239–1253.
10. Dunwoodie SL. 2009. The role of hypoxia in development of the mammalian embryo. Dev Cell 17: 755–773.
11. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, Machulla HJ, Bares R. 2005. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 46: 253–260.
12. Fu Y, Reyon D, Joung JK. 2014. Targeted genome editing in human cells using CRISPR/Cas nucleases and truncated guide RNAs. Methods Enzymol 546: 21–45.
13. Gameiro PA, Yang J, Metelo AM, Perez-Carro R, Baker R, Wang Z, Arreola A, Rathmell WK, Olumi A, Lopez-Larrubia P, et al. 2013. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab 17: 372–385.
14. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883–892.
15. Guo X, Tian Z, Wang X, Pan S, Huang W, Shen Y, Gui Y, Duan X, Cai Z. 2015. Regulation of histone demethylase KDM6B by hypoxia-inducible factor-2α. Acta Biochim Biophys Sin (Shanghai) 47: 106–113.
16. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. 1996. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56: 4509–4515.
17. Hook SS, Lin JJ, Dutta A. 2007. Mechanisms to control rereplication and implications for cancer. Curr Opin Cell Biol 19: 663–671.
18. Jiang XR, Jimenez G, Chang E, Frolkis M, Kusler B, Sage M, Beeche M, Bodnar AG, Wahl GM, Tlsty TD, et al. 1999. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nat Genet 21: 111–114.
19. Jopling C, Sune G, Faucherre A, Fabregat C, Izpisua Belmonte JC. 2012. Hypoxia induces myocardial regeneration in zebrafish. Circulation 126: 3017–3027.
20. Junttila MR, de Sauvage FJ. 2013. Influence of tumour microenvironment heterogeneity on therapeutic response. Nature 501: 346–354.
21. Khattar V, Thottassery JV. 2013. Cks1: structure, emerging roles and implications in multiple cancers. J Cancer Ther 4: 1341– 1354.
22. Krieg AJ, Rankin EB, Chan D, Razorenova O, Fernandez S, Giaccia AJ. 2010. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1α enhances hypoxic gene expression and tumor growth. Mol Cell Biol 30: 344–353.
23. Lee HY, Yang EG, Park H. 2013. Hypoxia enhances the expression of prostate-specific antigen by modifying the quantity and catalytic activity of Jumonji C domain-containing histone demethylases. Carcinogenesis 34: 2706–2715.
24. Levinson DF, Duan J, Oh S, Wang K, Sanders AR, Shi J, Zhang N, Mowry BJ, Olincy A, Amin F, et al. 2011. Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. Am J Psychiatry 168: 302–316.
25. Lewis PW, Muller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA, Garcia BA, Muir TW, Becher OJ, Allis CD. 2013. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340: 857–861.
26. Manning AL, Longworth MS, Dyson NJ. 2010. Loss of pRB causes centromere dysfunction and chromosomal instability. Genes Dev 24: 1364–1376.
27. Martin-Ezquerra G, Salgado R, Toll A, Baro T, Mojal S, Yebenes M, Garcia-Muret MP, Sole F, Quitllet FA, Espinet B, et al. 2011. CDC28 protein kinase regulatory subunit 1B (CKS1B) expression and genetic status analysis in oral squamous cell carcinoma. Histol Histopathol 26: 71–77.
28. Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, et al. 2014. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343: 72–76.
29. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, et al. 2014. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344: 1396–1401.
30. Paw BH, Zon LI. 1999. Primary fibroblast cell culture. Methods Cell Biol 59: 39–43.
31. Perou CM. 2010. Molecular stratification of triple-negative breast cancers. Oncologist 15: 39–48.
32. Rofstad EK. 2000. Microenvironment-induced cancer metastasis. Int J Radiat Biol 76: 589–605.
33. Shaughnessy J. 2005. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 10: 117–126.
34. Shi L, Wang S, Zangari M, Xu H, Cao TM, Xu C, Wu Y, Xiao F, Liu Y, Yang Y, et al. 2010. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget 1: 22–33.
35. Smith EH, Janknecht R, Maher LJ III. 2007. Succinate inhibition of α-ketoglutarate-dependent enzymes in a yeast model of paraganglioma. Hum Mol Genet 16: 3136–3148.
36. Solaini G, Baracca A, Lenaz G, Sgarbi G. 2010. Hypoxia and mitochondrial oxidative metabolism. Biochim Biophys Acta 1797: 1171–1177.
37. Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, Steinberg S, Fossdal R, Sigurdsson E, Sigmundsson T, Buizer-Voskamp JE, et al. 2008. Large recurrent microdeletions associated with schizophrenia. Nature 455: 232–236.
38. Stratton MR, Campbell PJ, Futreal PA. 2009. The cancer genome. Nature 458: 719–724.
39. Tan MK, Lim HJ, Harper JW. 2011. SCF(FBXO22) regulates histone H3 lysine 9 and 36 methylation levels by targeting histone demethylase KDM4A for ubiquitin-mediated proteasomal degradation. Mol Cell Biol 31: 3687–3699.
40. Tang YC, Amon A. 2013. Gene copy-number alterations: a cost– benefit analysis. Cell 152: 394–405.
41. Tower J. 2004. Developmental gene amplification and origin regulation. Annu Rev Genet 38: 273–304.
42. Van Rechem C, Black JC, Abbas T, Allen A, Rinehart CA, Yuan GC, Dutta A, Whetstine JR. 2011. The SKP1-Cul1-F-box and leucine-rich repeat protein 4 (SCF–FbxL4) ubiquitin ligase regulates lysine demethylase 4A (KDM4A)/Jumonji domain-containing 2A (JMJD2A) protein. J Biol Chem 286: 30462–30470.
43. Van Rechem C, Black JC, Boukhali M, Aryee MJ, Graslund S, Haas W, Benes CH, Whetstine JR. 2015. Lysine demethylase KDM4A associates with translation machinery and regulates protein synthesis. Cancer Discov 5: 255–263.
44. Vaupel P. 2004. The role of hypoxia-induced factors in tumor progression. Oncologist 9: 10–17.
45. Wang XC, Tian J, Tian LL, Wu HL, Meng AM, Ma TH, Xiao J, Xiao XL, Li CH. 2009. Role of Cks1 amplification and overexpression in breast cancer. Biochem Biophys Res Commun 379: 1107–1113.
46. Wang L, Chang J, Varghese D, Dellinger M, Kumar S, Best AM, Ruiz J, Bruick R, Pena-Llopis S, Xu J, et al. 2013. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nat Commun 4: 2035.
47. Wang W, He YF, Sun QK, Wang Y, Han XH, Peng DF, Yao YW, Ji CS, Hu B. 2014. Hypoxia-inducible factor 1α in breast cancer prognosis. Clin Chim Acta 428: 32–37.
48. Whetstine JR, Nottke A, Lan F, Huarte M, Smolikov S, Chen Z, Spooner E, Li E, Zhang G, Colaiacovo M, et al. 2006. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell 125: 467–481.
49. Winter SC, Buffa FM, Silva P, Miller C, Valentine HR, Turley H, Shah KA, Cox GJ, Corbridge RJ, Homer JJ, et al. 2007. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res 67: 3441– 3449.